CoChat

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is a highly heterogeneous disease, for which prognosis has been relegated to clinicopathologic staging for decades. There is a need to stratify subpopulations of CRC on a molecular basis to better predict outcome and assign therapies. Here we report targeted exome-sequencing of 1,321 cancer-related genes on 468 tumour specimens, which identified a subset of 17 genes that best classify CRC, with APC playing a central role in predicting overall survival. APC may assume 0, 1 or 2 truncating mutations, each with a striking differential impact on survival. Tumours lacking any APC mutation carry a worse prognosis than single APC mutation tumours; however, two APC mutation tumours with mutant KRAS and TP53 confer the poorest survival among all the subgroups examined. Our study demonstrates a prognostic role for APC and suggests that sequencing of APC may have clinical utility in the routine staging and potential therapeutic assignment for CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms11743

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Multidimensional scaling plot for the correlation of highly mutated genes. This plot (Euclidean distance model) graphically depicts the correlation of the 17 genes, with elevated non-silent mutation rates presented in Table 2 along with MSI-H status and presence of distant metastasis (D-meta). The most significant correlated genes BRAF, APC, KRAS, TP53 and MSI-H and D-meta are highlighted in red. BRAF is very close to (having strong positive correlation with) MSI-H but is anticorrelated with (far apart from) distant metastasis. Conversely, the partnering mutations (APC, KRAS and TP53) are comparatively close to each other and are with distant metastasis. Notably, ITGB4, CSMD3 and CBX4 are much closer to MSI-H than D-meta on the plot. FAM123B, also called AMER1, is a chromosome X-linked mutation, and 38/51 patients with mutations are female.
Figure 1 Multidimensional scaling plot for the correlation of highly mutated genes. This plot (Euclidean distance model) graphically depicts the correlation of the 17 genes, with elevated non-silent mutation rates presented in Table 2 along with MSI-H status and presence of distant metastasis (D-meta). The most significant correlated genes BRAF, APC, KRAS, TP53 and MSI-H and D-meta are highlighted in red. BRAF is very close to (having strong positive correlation with) MSI-H but is anticorrelated with (far apart from) distant metastasis. Conversely, the partnering mutations (APC, KRAS and TP53) are comparatively close to each other and are with distant metastasis. Notably, ITGB4, CSMD3 and CBX4 are much closer to MSI-H than D-meta on the plot. FAM123B, also called AMER1, is a chromosome X-linked mutation, and 38/51 patients with mutations are female.CC BY · PubMed Central
Figure 2 Immunohistochemical staining of β-catenin in 52 colorectal cancers. (a) Representative images for APC groups (APCwt, one mutation, two mutations and one mutation plus inferred allelic loss ‘LOH'). Scale bar (bottom right), 20 μm. (b) Allred scores for nuclear (solid bars), cyto (unfilled bars) and membranous (hatched bars) staining of β-catenin in the APC groups: APCwt (n=14), one mutation (n=17), two mutations (n=12) and one mutation plus inferred allelic loss ‘LOH' (n=9). Error bar represents s.e.m. P=0.014 is for two-tailed, unequal variance Welch t-test. See detailed score information for individual tumours in Supplementary Table 7.
Figure 2 Immunohistochemical staining of β-catenin in 52 colorectal cancers. (a) Representative images for APC groups (APCwt, one mutation, two mutations and one mutation plus inferred allelic loss ‘LOH'). Scale bar (bottom right), 20 μm. (b) Allred scores for nuclear (solid bars), cyto (unfilled bars) and membranous (hatched bars) staining of β-catenin in the APC groups: APCwt (n=14), one mutation (n=17), two mutations (n=12) and one mutation plus inferred allelic loss ‘LOH' (n=9). Error bar represents s.e.m. P=0.014 is for two-tailed, unequal variance Welch t-test. See detailed score information for individual tumours in Supplementary Table 7.CC BY · PubMed Central
Figure 3 Kaplan–Meier survival analysis. (a) MSI tumours by BRAF mutation, (b) MSS tumours by APC groups (APCwt, APC, APC/KRAS, APC/TP53, APC/KRAS/TP53), (c) MSS tumours by the number of truncating mutations (0, 1, 2) in the APC gene, (d) MSS tumours by both APC groups and the number of APC mutations. A−APC, K−KRAS, P−TP53. Five classes: Class 0: APC wild type; Class 1: APC(1), APC(1)/KRAS, APC(1)/TP53; Class 2: APC(2), APC(2)/KRAS, APC(2)/TP53; Class 3: APC(1)/KRAS/TP53; Class 4: APC(2)/KRAS/TP53. A(1) or APC (1) represents one APC mutation and A(2) or APC (2) represents two APC mutations.
Figure 3 Kaplan–Meier survival analysis. (a) MSI tumours by BRAF mutation, (b) MSS tumours by APC groups (APCwt, APC, APC/KRAS, APC/TP53, APC/KRAS/TP53), (c) MSS tumours by the number of truncating mutations (0, 1, 2) in the APC gene, (d) MSS tumours by both APC groups and the number of APC mutations. A−APC, K−KRAS, P−TP53. Five classes: Class 0: APC wild type; Class 1: APC(1), APC(1)/KRAS, APC(1)/TP53; Class 2: APC(2), APC(2)/KRAS, APC(2)/TP53; Class 3: APC(1)/KRAS/TP53; Class 4: APC(2)/KRAS/TP53. A(1) or APC (1) represents one APC mutation and A(2) or APC (2) represents two APC mutations.CC BY · PubMed Central
Figure 4 Expression (log2) comparison of MSS tumours in five classes (n=399). (a) EMT signature scores1729, (b) RAS_AZ signature scores16, (c) the 64 β-catenin-targeted genes28 and (d) APC mRNA expression (mean of eight APC probes). Five classes: Class 0: APC wild type; Class 1: APC(1), APC(1)/KRAS, APC(1)/TP53; Class 2: APC(2), APC(2)/KRAS, APC(2)/TP53; Class 3: APC(1)/KRAS/TP53; Class 4: APC(2)/KRAS/TP53. APC (1) represents one APC mutation and APC (2) represents two APC mutations. Error bars represent s.e.m. The two-tailed, unequal variance Welch t-test was used to assess the statistical significance of comparison. Unadjusted P-values of <0.05 are shown. Notably, eight samples without suitable microarray data were excluded from 407 MSS CRCs. Class 0 tumours were significantly more ‘mesenchymal-like' than all four other classes (a), while AKP-related Classes 3 and 4 had stronger RAS activation (b). Compared with Class 0 tumours, WNT activation, as measured by the 64 WNT target genes, was observed in APC-mutated Class 1 (P=0.0047), Class 3 (P=0.0013) and Class 4 (P=0.0018; c).
Figure 4 Expression (log2) comparison of MSS tumours in five classes (n=399). (a) EMT signature scores1729, (b) RAS_AZ signature scores16, (c) the 64 β-catenin-targeted genes28 and (d) APC mRNA expression (mean of eight APC probes). Five classes: Class 0: APC wild type; Class 1: APC(1), APC(1)/KRAS, APC(1)/TP53; Class 2: APC(2), APC(2)/KRAS, APC(2)/TP53; Class 3: APC(1)/KRAS/TP53; Class 4: APC(2)/KRAS/TP53. APC (1) represents one APC mutation and APC (2) represents two APC mutations. Error bars represent s.e.m. The two-tailed, unequal variance Welch t-test was used to assess the statistical significance of comparison. Unadjusted P-values of <0.05 are shown. Notably, eight samples without suitable microarray data were excluded from 407 MSS CRCs. Class 0 tumours were significantly more ‘mesenchymal-like' than all four other classes (a), while AKP-related Classes 3 and 4 had stronger RAS activation (b). Compared with Class 0 tumours, WNT activation, as measured by the 64 WNT target genes, was observed in APC-mutated Class 1 (P=0.0047), Class 3 (P=0.0013) and Class 4 (P=0.0018; c).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

Items 201–221 of 221

Metadata

Authors
Schell, M. J., Yang, M., Teer, J. K., Lo, F. Y., Madan, A., Coppola, D., Monteiro, A. N. A., Nebozhyn, M. V., Yue, B., Loboda, A., Bien-Willner, G. A., Greenawalt, D. M., & Yeatman, T. J.
Affiliations
  • Moffitt Cancer Center (US)
  • LabCorp (United States) (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
  • Schell, Michael J.
  • Yeatman, Timothy J.
Venue
Nature Communications
Published
2016-06-15
Volume
7
Issue
1
Pages
11743-11743
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2421455087
Cited by
207
References
63
Citations by year
2026: 8 · 2025: 13 · 2024: 16 · 2023: 21 · 2022: 31 · 2021: 32 · 2020: 31 · 2019: 19 · 2018: 16 · 2017: 16 · 2016: 3
FWCI
16.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Moffitt Cancer Center (P30-CA76292)
  • National Institutes of Health
  • National Cancer Institute (P30‐CA76292, CA76292, U01CA157960, P30CA076292)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
colorectal cancer, APC mutation, prognostic factors, overall survival, KRAS, TP53, truncating mutations, molecular subtyping, targeted exome sequencing, treatment stratification
MeSH terms
Cell Nucleus, Humans, Mutation, Neoplasm Metastasis, Prognosis, Staining and Labeling, Colorectal Neoplasms, Proportional Hazards Models, Statistics, Nonparametric, Adenomatous Polyposis Coli Protein, Wnt Proteins, beta Catenin, Genes, Neoplasm, Kaplan-Meier Estimate, Microsatellite Instability, Mutation Rate, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.